EnCare Biotech, a life sciences spin-out of the University Medical Centre Utrecht, has secured €5.5m ($6.84m) at launch.
The investment was co-led by Index Ventures and Thuja Capital. Joining in participation was Utrecht Holdings, the investment company of Utrecht University and the Medical Centre. All three will take places on EnCare’s board of directors.
The company is developing therapies to prevent heart failure following a heart attack.